OUR PRODUCTS

MOBILE APPS

GENERAL INFO

AIM

Stock ticker: ASE

PRICE

CHANGE

CAPITALIZATION

AIM ImmunoTech (AIM) Ownership - Who owns AIM ImmunoTech?

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies... Show more

Get AI intraday signals

#MovingAverage #Momentum #MACD #Pattern #RSI #Stochastic #Aroon #Bollinger

Profile

Industry

N/A

Address

2117 SW Highway 484

Phone

+1 352 448-7797

Employees

Web

https://www.aimimmuno.com

Details

Group

Domestic Stock Funds

Fundamentals

AIM

Capitalization

6.42M

P/E Ratio

N/A

Risk (Beta)

1.66

Dividend Yield

N/A

Total Cash

N/A

Total Cash/Share

N/A

Total Debt

2.52M

Total Debt/Equity

N/A

Projected Growth (PEG Ratio)

N/A

Revenue/Share (as % of the share price)

0.24%

Revenue

146K

ROE

N/A

Book Value

-3.86M

P/B Ratio

2.89

Cash Flow

N/A

Earnings

-24

Average Daily Volume YTD

N/A

Common Shares Outstanding - Security Level

72K

Current Ratio

0.26

Current Revenue Per Employee

695.65

Dividends Per Share - Security

N/A

EBITDA

-14.33M

Float

N/A

Float - Current

N/A

Gross Income Margin

37.50

Revenue To Assets

-135.56

Shares Held By Institutions

977K

Shares Outstanding - Current

764K

Total Liabilities

10.1M

Total Volume MTD

N/A

Value

N/A

Gain YTD

-57.576

View a ticker or compare two or three

Compare

AIM

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For AIM
(Try 14 days for Free)

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading

A.I. Advisor

published General Information

General Information

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology